InsidersTradesSigma
Follow the Acrivon Therapeutics, Inc. share price and the full management transaction log of the company, a publicly traded company based in United States. Shares trade on the US market, under the supervision of SEC (Form 4). Market capitalisation: €66.8m. The latest transaction was disclosed on 6 August 2026 (Cession). Among the most active insiders: Miller Mary. The full history is openly available.
110
Insider Decl.
n/a
Thresholds
€24m
5 ops.
Buy Volume
€3m
9 ops.
Sell Volume
46Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 6 August 2026
Declarations110 total
1,142 shares@ US$1.57Common StockSEC:0000905148-26-003499:0
573 shares@ US$1.760.0013% mcap1.8% of flowCommon StockSEC:0000905148-26-003334:0
13,729 shares@ US$1.790.5% of flowCommon StockSEC:0000905148-26-002652:0
3,888,888 shares@ US$1.808.95% mcap17.6% of flowCommon StockSEC:0001231919-26-000396:0
558 shares@ US$1.781.9% of flowCommon StockSEC:0000905148-26-001768:0
14,265 shares@ US$1.530.5% of flowCommon StockSEC:0000905148-26-001010:0
116 shares@ US$1.634.8% of flowCommon StockSEC:0000905148-26-000939:0
217 shares@ US$1.630.6% of flowCommon StockSEC:0000905148-26-000937:0
471 shares@ US$1.633.0% of flowCommon StockSEC:0000905148-26-000936:0
723 shares@ US$1.631.5% of flowCommon StockSEC:0000905148-26-000935:0
1,302 shares@ US$1.630.0% of flowCommon StockSEC:0000905148-26-000934:0
659 shares@ US$1.982.3% of flowCommon StockSEC:0000905148-26-000281:0
49,000 shares@ US$1.6761.7% of flowCommon StockSEC:0000905148-26-000226:0
Canonical exit: 14 Apr 2026 (T+90)
8,832 shares@ US$1.698390.9% of flowCommon StockSEC:0000905148-26-000225:0
Canonical exit: 14 Apr 2026 (T+90)
10,000 shares@ US$1.721821.8% of flowCommon StockSEC:0000905148-26-000212:0
Canonical exit: 13 Apr 2026 (T+90)
19,904 shares@ US$2.301.0% of flowCommon StockSEC:0000905148-25-004179:0
59,765 shares@ US$2.242.9% of flowCommon StockSEC:0000905148-25-004127:0
490 shares@ US$2.240.0% of flowCommon StockSEC:0000905148-25-004127:1
613 shares@ US$2.242.3% of flowCommon StockSEC:0000905148-25-004128:0
403 shares@ US$2.243.8% of flowCommon StockSEC:0000905148-25-004129:0
184 shares@ US$2.240.8% of flowCommon StockSEC:0000905148-25-004130:0
99 shares@ US$2.246.3% of flowCommon StockSEC:0000905148-25-004131:0
558 shares@ US$1.811.9% of flowCommon StockSEC:0000905148-25-003637:0
284 shares@ US$1.810.9% of flowCommon StockSEC:0000905148-25-003506:0
19,905 shares@ US$1.320.6% of flowCommon StockSEC:0000905148-25-003121:0
25 of 110 declarations
About Acrivon Therapeutics, Inc.
Acrivon Therapeutics, Inc. is a biopharmaceutical company focused on developing targeted therapies for cancer treatment. It utilizes a biomarker platform to identify patients who are likely to benefit from its treatments.